Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OTTO study of omalizumab in chronic urticaria
2010-022864-12Phase 2Completed
- Sponsor
- Medical Faculty Magdeburg
- Start
- Feb 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of omalizumab in chronic urticaria (CU), sponsored by Medical Faculty Magdeburg. Primary endpoint: Clinical effect after 16 weeks of treatment. Started Feb 2011; status: completed.
02
Drugs
omalizumab
03
Conditions
chronic urticaria (CU)
Beyond the preview
Go deeper on 2010-022864-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022864-12.